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ABSTRACT: N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT),
which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1)
to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC50 = 2 nM) and T. brucei (EC50 =
2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This
compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for
further optimization.
■ INTRODUCTION
Human African trypanosomiasis (HAT) or sleeping sickness is
caused by two subspecies of the protozoan parasite
Trypanosoma brucei (T. brucei gambiense and T. b. rhodesiense),
which are transmitted by the bite of an infected tsetse fly. The
disease, which is fatal unless treated, has two stages: an initial
peripheral infection during which the parasites are found in the
bloodstream and gives rise to nonspecific symptoms; a second
stage when parasites enter the central nervous system, causing
the classic symptoms of HAT, eventually leading to coma and
death. Currently there are five treatments available, although
none of them are satisfactory because of toxicity, treatment
failures, and the requirement for parenteral administration,
which is inappropriate in a rural African setting.1
The enzyme N-myristoyltransferase (NMT) represents a
promising drug target, since its essentiality has been
demonstrated in many organisms. Moreover, in T. brucei,
RNAi knockdown of NMT has been shown to be lethal in cell
culture and to abrogate infectivity in a mouse model of
infection.2,3
NMT catalyzes the co-translational transfer of myristate from
myristoyl-CoA to the N-terminal glycine of a subset of
eukaryotic proteins, a modification that has been implicated
in subcellular targeting to membrane locations and/or activa-
tion and stabilization of the substrate protein (Figure 1).4
While there is an incomplete knowledge of the targets of NMT
in T. brucei and their subsequent downstream effects, bio-
informatic analysis suggests there are in excess of 60 potential
substrates,2 two of which (ADP-ribosylation factor-1 protein
(ARF-1) and ADP-ribosylation factor-like protein (ARL-1))
have been characterized and shown to be essential for
bloodstream parasite viability.5 Therefore, inhibition of the
enzyme would be expected to have pleiotropic effects through
its potential to affect multiple pathways.
The enzyme operates via a Bi-Bi mechanism in which
binding of myristoyl-CoA induces a conformational rearrange-
ment that reveals the peptide binding site.2 The myristate
group is then transferred in a nucleophilic addition−elimination
reaction, which is followed by sequential release of CoA followed
by the myristoylated protein. Several industrial research groups
have targeted NMT from the yeast Candida albicans, initially
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developing peptidomimetic inhibitors,6−10 which had limited
cellular activity. More recently promising small molecule
inhibitors, based around benzofuran11−14 and benzothia-
zole15,16 cores, have been discovered.2 Development of these
compounds as antifungal agents has not been continued
presumably because of the inability to derive compounds with
broad-spectrum antifungal activity.
We have previously reported biological studies that
demonstrate the validity of T. brucei NMT (TbNMT) as a
druggable target for HAT, using the prototypic TbNMT
inhibitor DDD85646 (63).17,18 In this paper, we describe the
medicinal chemistry that led to the discovery of this key
inhibitor.
■ RESULTS AND DISCUSSION
Hit Discovery. TbNMT entered our discovery portfolio for
HAT following a positive assessment of its potential as a drug
target, according to our published criteria.19 When the project
commenced, there was a clinical need for safe oral drugs active
in the first acute stage of the disease, in addition to the most
favored profile of activity in both stages of HAT. Consequently,
there was not an absolute requirement for compounds to access
the CNS, relaxing some of the criteria required for compound
progression, for example, polar surface area (PSA). Screening of
a selection of antifungal compounds against TbNMT (a reposition-
ing or piggy-back approach4) by Smith and colleagues at the
University of York, U.K., failed to identify substantially potent
or druglike compounds.20 Similarly we did not observe
significant inhibition of TbNMT with the potential benzofuran
leads RO-09-460913 and RO-09-487913 (see Supporting
Information), or related analogues, originally developed by
Roche against the fungal species C. albicans. Subsequently,
comparison of X-ray crystal structures has revealed that there
are substantial differences between the C. albicans NMT
structure and that of NMT from Leishmania major. The
T. brucei NMT enzyme (for which there is no structure to date)
is most closely related to that of the L. major enzyme (74%
sequence identity overall, 94% sequence identity within the
active site).
In the absence of any reported tractable chemical start points,
we opted to carry out a high-throughput screen (HTS) using
our 63362-compound diversity library.21 A convenient
homogeneous scintillation−proximity based assay in 384-well
plate format was used to screen compounds, which employed
TbNMT, tritiated myristoyl-CoA, the biotinylated peptide
CAP5.522 (sequence GCGGSKVKPQPPQAK), and streptavi-
din coated polyvinyltoluene scintillation beads (Figure 1).
Compounds were initially screened in singlicate at 30 μM, and
the screen performance was excellent, with a mean (±SD) Z′ =
0.79 ± 0.05 (n = 210 plates). Compounds showing greater than
50% inhibition were reconfirmed in duplicate, and then potency
was determined via 10-point half-log dilution curves (30 μM to
1.5 nM). Hit compounds shown to nonspecifically inhibit the
assay signal were eliminated from further evaluation. Key
compounds were also screened against human NMT-1
(HsNMT-1) and against the bloodstream form of the T. b.
brucei (BSF427, VSG118) parasite in culture. Inhibition of
proliferation of human MRC5 cells was used as an initial
toxicity counterscreen (see Experimental Section).
Optimization of the Pyrazole Sulfonamides. Of the
compounds confirmed as validated hits by testing of
resynthesized material, we opted to focus our attention on
compound 1 (Figure 2), the most potent example of a series
of nine N-pyrazole arylsulfonamides identified by the HTS.
Figure 1. Format and performance of the HTS assay: (A) % inhibition and IC50 values determined using a scintillation proximity assay;
2
(B) frequency histogram representing % inhibition values for the HTS. Hits are designated as those compounds that displayed a % inhibition
equal to or greater than 3 standard deviation units above the mean (40% inhibition). (C) Comparison of replicate % inhibition values for the
352 primary screen hits.
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The compound had potencies of 1.9 and 22 μM against
TbNMT and HsNMT-1, respectively, demonstrating encourag-
ing selectivity over the human isoform while having
promising ligand efficiency (LE = 0.34).23 Moreover, 1 had
moderate activity against the parasite in vitro (EC50 = 21 μM).
Testing of 1 against varying concentrations of substrate peptide
indicated that it is competitive for substrate binding and hence
binds to the peptide binding site. Thus, changing the
concentration of CAP5.5 from 0.5 to 16 μM caused the IC50
for TbNMT to change from 1.0 to 4.3 μM, as previously
described.17
In the absence of any structural information for TbNMT to
guide rational inhibitor design, we adopted a pragmatic
chemistry-driven approach through which we aimed to (i)
understand the importance for binding of existing parts of the
inhibitor with a view to optimizing these and (ii) identify
appropriate positions from which to extend the molecule and
seek further ligand−protein interactions that improve affinity. A
systematic program was therefore carried out to define the key
pharmacophoric features of 1. A common requirement for high
potency in previously reported NMT inhibitors is a basic
functionality that interacts electrostatically with the C-terminal
carboxylic acid of NMT, in the region of the active site
normally occupied by the amino group of the peptide
substrate’s terminal glycine. Although the binding mode of 1
was unknown from the outset, we anticipated that incorpo-
ration of a basic center in an appropriate location would
significantly enhance potency of the hits, as experienced by
previous NMT inhibitor programs.7−14,16,17,24
Investigation of SAR at the Pyrazole Group. Initially
we investigated changes around the pyrazole of 1 (Table 1).
Compounds were prepared by reaction of an amine with
3-methoxy-2,4,5-trimethylbenzenesulfonyl chloride. The pyrazole
N-substituent could be modified by using a standard alkylation
reaction on the symmetrical intermediate (2) (Scheme 1).
Removal of the N-methyl substituent of 1 (2) and
replacement of the N-methyl substituent with a larger n-propyl
(3) or isopropyl (4) group significantly reduced activity.
A number of potential aromatic replacements of the pyrazole,
including imidazopyridine (7), pyridine (8), substituted pyri-
dine (9), isoxazole (10 and 11), phenyl (12), and benzyl
(13) together with addition of a methylene between the
sulfonamide and the pyrazole (14), were investigated. The only
replacements that gave some potency were the 2-methylpyridyl
derivative 9 (IC50 = 10 μM) and the isoxazole derivative 10
(IC50 = 19 μM), although these were both less potent than
the original N-methylpyrazole 1 (IC50 = 1.9 μM). In combina-
tion, these results implied that the pyrazole N2 nitrogen was
interacting with the enzyme as a hydrogen bond acceptor, since
removal of it (e.g., 12) or increasing steric bulk around it (3 and 4)
caused marked reductions in potency. Only isoelectronic hetero-
cycles 9 and 10, with a similarly located hydrogen bonding
acceptor capability, retained activity. Therefore, the trimethylpyr-
azole moiety of 1 was retained in further studies.
Investigation of SAR at the Sulfonamide Group. A
series of analogues were made to investigate changes at the
sulfonamide linker of compound 15 (Table 2). These were
prepared as described in Scheme 2. In general, amides and
sulfonamides were prepared by reaction of the appropriate
amine with a benzoyl chloride or sulfonyl chloride, respectively.
Replacement of the sulfonamide of 15 with an amide (17) as
well as reversing the sulfonamide (19) and amide (24) led to a
loss of activity. This suggests that either both sulfonamide
oxygen atoms are involved in binding, or the sulfonamide causes
a conformational effect important for locating the pyrazole ring
relative to the aromatic system. It is known from crystallo-
graphic studies that N-substituted sulfonamides prefer to adopt a
“kinked” conformation with substituents on the same side of the
S−N bond.25 Therefore, amide 17 was N-substituted (18) with
the aim of forcing the amide into a similar cis-conformation, but
this compound was also inactive. Similarly, using an amine (21) or
ether (22) as a linker led to a reduction in activity, presumably due
Figure 2. Structure and biological activity of compound 1.
Table 1. Activities of Pyrazoles and Pyrazole Replacements
against TbNMTa
aIC50 values are shown as mean values of two or more determinations.
Standard deviation is typically within 2-fold from the IC50.
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to their greater flexibility and/or loss of hydrogen bond acceptor
capability. Addition of an extra methylene (23) caused a loss of
activity. Only the sulfone replacement (20) showed some activity
(IC50 = 42 μM), although this was less than the corresponding
sulfonamide (15).
The sulfonamide could be N-methylated with little effect on
activity (16), suggesting that the sulfonamide NH group is not
a participant in a significant interaction with TbNMT. Further
substitution of the sulfonamide nitrogen of a related compound
(29) with a variety of simple alkyl groups, while not unduly
detrimental, did not significantly enhance activity (see Table S1
in the Supporting Information), with potencies observed in the
range of 0.5 μM (R = methyl) to 9.3 μM (R = CH2CCCH3).
Investigation of SAR at the Aryl Group. An inves-
tigation of diverse substitutions of the arylsulfonyl ring was
carried out. Compounds were prepared using parallel synthesis
techniques (Scheme 3). We initially prepared 60 analogues (see
Table S2 in the Supporting Information); key compounds are
shown in Table 3.
In general, we found SAR around the ring to be
comparatively flat, with even relatively sterically demanding
substitutions in ortho-, meta-, and particularly para-positions
tolerated, albeit without significant enhancements in potency.
Given the largely inconsequential effect on potency of groups
around the aromatic ring and the ability to tolerate even large
substituents (e.g., 31, IC50 = 1.9 μM), we speculated that these
substituents occupy a “sequence insensitive” region of the
active site (i.e., the region that accommodates residues 2−4 of
the substrate peptide), which is known to be capable of bind-
ing a variety of residues but to favor hydrophobic residues.26,27
Given the approximately 10-fold improvement in activity obtained
with the 2,6-dichloro substitution of 28 (IC50 = 1.0 μM)
compared with 25 (IC50 = 12 μM), we continued to search for
improvements in activity using this framework and utilized
compound 29 in a Suzuki reaction for the preparation of a
small speculative library of biaryl derivatives (see Table S3 in
the Supporting Information). Of the 14 analogues prepared,
only 36 (IC50 = 0.9 μM) had activity comparable to that of 29.
Additional Protein−Ligand Interactions from an
Aminopyridine Scaffold. Since relatively bulky substitution
was best tolerated in the para-position of the sulfonamide
aromatic system (e.g., 36), we thought it most appropriate to
seek additional protein−ligand interactions by probing from
this position. The aminopyridyl moiety did not appear to be
detrimental to binding per se (e.g., 31, IC50 = 1.9 μM);
therefore, an additional exploratory library of 44 compounds
was produced using a nucleophilic aromatic substitution
reaction between chloropyridine 37 and a diverse set of
commercially available amines (Scheme 4). Selected com-
pounds are shown in Table 4 (full data can be seen in Table S4
in the Supporting Information).
Scheme 1a
aReagents: (i) NH2R, pyridine; (ii) R
1Br, Cs2CO3, DMF.
Table 2. Activities of Sulfonamide Replacements against TbNMTa
aIC50 values are shown as mean values of two or more determinations. Standard deviation is typically within 2-fold from the IC50.
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Again, a variety of substituents were tolerated, but with flat
SAR, with activity generally in the low micromolar range.
However, two compounds were particularly noteworthy because
of the striking difference in potency despite their structural sim-
ilarity. Compounds 41 (IC50 = 38 μM) and 42 (IC50 = 0.14 μM)
differ only in having a morpholine or a methylpiperazine at the
terminus of an ethyl linkage. We attributed the greater potency
of 42 to its potential to form an electrostatic interaction via the
protonatable terminal amine, since this approximately 100-fold
improvement in activity is consistent with formation of a ligand−
protein salt bridge, typically worth 10−400 kJ/mol. This
interaction would not be possible via the morpholine of 41. We
subsequently demonstrated through surrogate crystallographic
studies in LmNMT that this is the most probable explanation for
the increase in activity against TbNMT (see Structural Studies).
Furthermore, replacement of the basic terminal nitrogen of 42
with a methylene (i.e., 44, IC50 = 14 μM) gave a large drop in
activity, consistent with our reasoning. Given that enzyme kinetic
studies using 1 indicated that this series binds in the peptide
binding site, we speculated that 42 forms a salt bridge with the
carboxyl group of the terminal residue of TbNMT (Val446), a
mechanistically vital residue for myristoyl transfer. Moreover, this
is an interaction that is found with all currently known inhibitors
of NMT that have very high potency.6−16
An important objective of target-based discovery pro-
grammes is to achieve compounds with high selectivity against
relevant human isoforms in order to minimize the risk of target-
driven toxicity. While there is a high degree of sequence
similarity between TbNMT and HsNMT-1 and -2 (41% identity,
69% similarity vs HsNMT-1; 44% identity, 68% similarity vs
HsNMT-2) particularly at the active site (83% identity, 90%
similarity vs both isoforms), fortuitously key compounds
demonstrate upward of 60-fold selectivity against HsNMT-1
(e.g., 42).
A number of interesting observations were made when we
further investigated a variety of analogues with pendent amines
(Table 4). Differences in pKa (calculated using ACDlabs
software, version 11.02) might account for the greater potency
of the piperidine analogue 47 (IC50 = 0.03 μM; pKa = 9.6),
which is 4-fold more active than the analogous piperazine 42
(IC50 = 0.14 μM; pKa = 7.9), and the lower potency of
imidazole 50 (IC50 = 1.3 μM; pKa = 7.1). We were somewhat
surprised that imidazole proved to be a poor substitute for an
alkylamine, since this finding is in contrast to that of Searle.7
The des-methylpiperazine 43 (IC50 = 1.0 μM; pKa = 9.3), which
we would expect to be more basic and therefore more potent,
was actually around 8-fold less active than 42 potentially
because of loss of a hydrophobic interaction at the terminal
methyl group. Moreover, the loss of this methyl group causes a
reduction in selectivity against HsNMT-1 compared to 42 (16-
fold vs more than 60-fold). The spacer length to the amine
could be varied; compare the two-carbon linker of 42 (IC50 =
0.14 μM) with the three-carbon linker of 49 (IC50 = 0.11 μM).
However, the linker length in compound 46 (IC50 = 2.1 μM)
would appear to be too short to optimally form the key
interaction with the terminal nitrogen. There were indications
that the orientation of the amine has an effect on activity (for
example, compare conformationally constrained analogues 51,
IC50 = 0.11 μM, 52, IC50 = 0.03 μM, and 40, IC50 = 0.36 μM)
in compounds where the amines are constrained in slightly
different orientations. Whereas methylation of the terminal
nitrogen appears to be beneficial for activity, higher
substitution, i.e., with isopropyl (45), phenyl (48), benzyl
(53) or tert-butyloxycarbonyl groups (54), was not tolerated.
Effect of Conformational Restraint on the Activity of
42. Having identified a key protein−ligand electrostatic
interaction in compounds typified by the prototype 42, we
continued to explore the concept of using conformational
restraint to orient the amine in an optimal manner to increase
potency. We chose to revisit the biaryl system of 36 as a
suitable scaffold from which to attach an amine moiety because
it conveyed the dual benefits of an unambiguous conformation
combined with the potency-enhancing effect of the 2,6-
dichlorophenyl moiety. A series of compounds was examined
where a protonatable nitrogen was attached in various positions
around the distal aryl ring (Table 5). Biaryl compounds 56, 59,
60, and 63 could be prepared using a Suzuki cross-coupling
reaction of commercially available arylboronic acids or esters
with 29, as the key step (Scheme 5). Alternatively, 29 could be
converted to the corresponding pinacolboronic ester by cross-
coupling with bispinacolatodiboron, allowing Suzuki reaction in
the reverse sense with the appropriate commercially available
Scheme 2a
aReagents: (i) 4-bromobenzenesulfonyl chloride, pyridine, DCM; (ii)
MeI, Cs2CO3, DMF; (iii) 4-bromobenzoyl chloride, pyridine, DCM;
(iv) isobutyraldehyde, AcOH, NaBH(OAc)3, DCM, 0 °C → room
temp; (v) 4-bromobenzyl bromide, K2CO3, KI, DMF; (vi) diisopropyl
azodicarboxylate, polymer supported PPh3, pyridine, DCM; (vii)
SOCl2, chloroform; (viii) sodium 4-bromobenzene sulfinate, H2O,
acetone.
Scheme 3a
aReagents: (i) pyridine, DCM.
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aryl bromide. Benzylamine compounds 57, 58, 61, and 62 were
prepared by reductive amination of benzaldehyde 55.
It is clear from these variations that substituents in the meta-
position consistently gave significantly higher potency than
those in the para-position; for example, compare 57 (IC50 =
1.2 μM) with 61 (IC50 = 0.005 μM); 58 (IC50 = 11 μM) with
62 (IC50 = 0.02 μM); and 59 (IC50 = 0.29 μM) with 63 (IC50 =
0.002 μM). A notable feature of compound 63, the most potent
of these constrained molecules, is that it also potently inhibits
the human isoform of NMT (TbNMT IC50 = 0.002 μM vs
HsNMT-1 IC50 = 0.003 μM). In addition, DDD85646 also
significantly inhibits the N-myristoyltransferase of other species,
including Leishmania major (LmNMT IC50 = 0.002 μM) and
Trypanosoma cruzi (TcNMT IC50 = 0.003 μM), which suggests
that this compound has potential utility as a lead for other
infectious diseases.
Pharmacology of 63. The intravenous (3 mg/kg) and
oral (10 mg/kg) pharmacokinetics of 63 have been assessed in
the female NMRI mouse, the species and strain used in the
acute animal model of HAT. Compound 63 has low blood
clearance (Clb = 6 mL min
−1 kg−1) and low volume of
distribution (Vd = 0.4 L/kg) with moderate half-life (t1/2 = 1.2 h)
and oral bioavailability (F = 19%). Compound 63
(DDD85646) as the hydrochloride salt has high aqueous
solubility (>15 mg/mL) and an appreciable unbound fraction
in mouse and human plasma (11% and 18%, respectively).17
The pharmacokinetic properties of 63 therefore have enabled
twice a day oral dosing, at a tolerated level, to achieve high
exposure of free drug relative to the EC90 for parasite
proliferation, making it a useful tool compound for validating
the target in the animal model of acute HAT. In this model, the
mice are infected with parasites and then treated with
compound 3 days later for 4 days. After treatment mice are
Scheme 4a
aReagents: (i) pyridine, DCM; (ii) HNR1R2, EtOH, 130−155 °C.
Table 3. Activities of Aryl Replacements against TbNMTa
aIC50 values are shown as mean values of two or more determinations. Standard deviation is typically within 2-fold from the IC50.
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monitored for levels of parasitemia. Cure is defined as mice
showing no signs of parasitemia 30 days after infection. The
Kaplan−Meier survival plot for female NMRI mice (n = 5 per
dose group) after infection with T. b. brucei s427 (inoculum
1 × 104 parasites) following oral treatment with 63 has been
described previously.17 The minimal orally efficacious dose was
found to be 12.5 mg/kg b.i.d. for 4 days. In contrast, the
minimal orally efficacious dose in the more refractory but
clinically relevant T. b. rhodesiense model of HAT was 50 mg/kg
b.i.d. for 4 days.17 This reduced sensitivity in vivo is not due to
reduced sensitivity of the compound in vitro but may be a
result of the known precedent for this species to occupy
privileged sites in vivo.17
Unfortunately, 63 has restricted brain penetration (brain/
blood ratio of <0.1), consistent with its physicochemical
properties (PSA = 92, MW = 495). Moreover, 63 also appears
to be a weak P-glycoprotein substrate as evidenced by the
Caco-2 efflux ratio (5.4) and the 3-fold increase in brain/blood
ratio observed in rat when the P-glycoprotein inhibitor
GF12091828 is co-administered, which at least partially explains
the lack of CNS penetration. The low concentration of 63
measured in brain might simply represent residual compound
present in the intravascular volume. That said, given its high
potency, 63 was progressed to a stage 2 HAT efficacy study at
the maximum tolerated dose (100 mg/kg po b.i.d.) to
investigate whether efficacy could be observed. Female NMRI
mice (n = 5 per dose group) were infected with T. b. brucei
GVR35 (inoculum 1 × 104 parasites), and treatment
commenced with 63 at 100 mg/kg po b.i.d. on day 21
postinfection for 5 days. No difference in survival time from
that of vehicle control animals was observed. In contrast,
melarsoprol (20 mg/kg ip once daily for 5 days), as positive
control, was fully curative (100% survival to 180 days
postinfection).
In terms of developability, the hepatic microsomal intrinsic
clearance in rat (0.5 mL min−1 g−1) and human (1.2 mL min−1 g−1)
is similar to that observed in mouse (0.6 mL min−1 g−1),
suggesting that blood clearance in these species should not be
too dissimilar from that observed in mouse. Compound 63
does not have a significant hERG liability (IC50 = 28 μM;
automated patch clamp) and no significant drug−drug
interaction liability (≤10% inhibition at 1 μM across the five
Table 4. Activities of Aryl Replacements against TbNMT and HsNMT-1a
aIC50 values are shown as mean values of two or more determinations. Standard deviation is typically within 2-fold from the IC50. n.d. = not
determined.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm201091t | J. Med. Chem. 2012, 55, 140−152146
major human isoforms CYP1A2, CYP2C9, CYP2C19,
CYP2D6, and CYP3A4) and therefore represents an exciting
druggable lead for further development of a stage 1 compound
for treatment of HAT.
Structural Studies. Attempts to crystallize the TbNMT
have been unsuccessful to date. However, during the course of
this project, we were able to obtain a structure for Leishmania
major NMT (LmNMT), which we have used as a surrogate
model for TbNMT. To further understand and confirm the
SAR, we have carried out a retrospective structural analysis of
selected ligands. This shows that 1, 29, 42, 59, and 63 occupy
the substrate binding groove of LmNMT (Figure 3A). The
pyrazole moieties superimpose well, occupying a pocket formed
predominantly by the side chains of Val81, Asp83, Phe88,
Phe90, Phe232, Ser330, Leu341, and Tyr345 that bind residues
4 and 5 of the peptide substrate (Figure 3B). This pocket has
Scheme 5a
aReagents: (i) B(OH)2R or B(OR)2R, K3PO4, DMF, H2O, Pd(dppf)Cl2.DCM; (ii) bis-pinacolatodiboron, K3PO4, THF, Pd(PPh3)4; (iii) RBr,
K3PO4, DMF, H2O, Pd(PPh3)4; (iv) HNR2, NaBH(OAc)3, CHCl3.
Table 5. Activities of Constrained Analogues against TbNMT, HsNMT-1, and T. bruceia
aIC50 values are shown as mean values of two or more determinations. Standard deviation is typically within 2-fold from the IC50.
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not been exploited in previously reported series of NMT
inhibitors developed against the C. albicans and Saccharomyces
cerevisiae enzymes because this pocket does not exist in these
two species. Instead of a serine, there is a phenylalanine that
occupies the same space as the pyrazole group of our ligands. In
LmNMT the pyrazole nitrogen lone pair forms a hydrogen
bond with the side chain hydroxyl group of Ser330. The
pyrazole N-methyl group interacts with the side chains of Val81
and the aromatic ring of Phe90. As seen from the SAR,
substituents larger than methyl at this nitrogen are not tolerated
because of the steric constraints exerted by this pocket. The
methyl in the 3-position of the pyrazole is packed against the
aromatic group of Phe88 and the side chain of Leu341.
Subsequent SAR studies (to be reported in due course) have
shown that this interaction provides an important contribution
to binding.
The sulfonamide moiety of 1, 59, and 63 hydrogen-bonds
through a highly coordinated water molecule to the side chain
of His219 and the backbone amides of Asp396 and Gly397.
This water molecule mimics the side chain hydroxyl of a Ser/
Thr residue, an important feature of the consensus sequence at
position 5 of the substrate peptide. There is a degree of
flexibility in the position and orientation of the sulfonamide
group; in 29 this moiety sits 0.8 Å closer to the Asn376-His219
pair and the water mediated hydrogen bonds are retained
(Supporting Information, Table S6). In 42 the hydrogen
bonding pattern of the sulfonamide is altered with the water
bridged interaction with His219 being replaced by a direct
contact between the sulfonamide oxygen and the side chain of
Asn376. This tendency for the sulfonamide to occupy various
positions makes it difficult to rationalize the exact importance
of its binding contribution, and we suggest that this group may
indeed only be important for optimal disposition of the
pyrazole relative to the central aromatic. The benzene rings of
1, 29, 59, and 63 do not form directional interactions with the
protein, though they stack above the side chain of Tyr217,
which lines the floor of the peptide binding site. Hydrophobic
packing is increased further by the two chlorine atoms of 63,
explaining their beneficial effect on potency. In 42, the pyridyl
nitrogen of this core ring potentially forms a water bridged
interaction with the side chains of Tyr345 and Tyr217 with the
linker nitrogen atom forming a water bridged interaction with
the backbone carbonyl of His398.
As previously observed, the presence of a basic functionality
near the C-terminal carboxylate results in large gains in
potency. However, in contrast to the Roche benzofuran that
interacts directly with the carboxylate group (PDB code 1IYL),
the series described here hydrogen-bond indirectly to the C-
terminal carboxylate via a network of water molecules (Figure
3C and Figure 3D). The residues that form this hydration site
Figure 3. Structural analysis of the pyrazole sulfonamide inhibitors of NMT. Panel A shows the binding mode of screening hit 1 bound to LmNMT
(gold C atoms) overlaid with the peptide GLYASKLA bound to ScNMT (PDB code 1IID, green C atoms). Panels B−F show the binding modes of
ligands (gold C atoms) bound to LmNMT (gray C atoms). Key water molecules are shown as red spheres and hydrogen bonds as dashed lines. Key
residues are labeled for clarity. Panel B shows the binding mode of 1 forming canonical interactions formed by pyrazole sulfonamide moieties. Panel
C shows the binding mode of 42 extending down toward the C-terminus, picking up water mediated interactions close to the terminal carboxylate.
Panel D shows in detail the hydrogen bonding interactions of the conserved hydration site around the C-terminus and the interaction with the
methylpiperazine of 42. Panel E shows the binding mode of the highly potent molecule 63 (PDB code 2WSA). Panel F shows the binding mode of
the para-substituted molecule 59 (gold C atoms) overlaid with the binding mode of the meta-substituted 63 (purple C atoms, partially transparent).
This illustrates the strained conformation of 59 and the altered hydrogen bonding pattern of the piperazine moiety.
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are all fully conserved throughout all NMTs. The alkyl chain of
42 extends down the peptide binding groove, allowing the
methylated nitrogen of the piperazine to hydrogen bond with a
water network formed by the side chains of Tyr92 and Asn167.
An additional hydrogen bond is formed between the water
molecule and the phenolic hydroxyl of Tyr80. The most potent
inhibitor 63 presents the terminal piperazine nitrogen 2.8 Å
from a tightly bound water molecule, and an additional
hydrogen bond is made with another water network close to
Met420. An additional water mediated hydrogen bond is
formed between the pyridyl nitrogen atom and the amide of
Gly205 (Figure 3E).
Comparison of the binding modes of 63 and its para-
substituted counterpart 59 provides some insight into the large
potency difference between the two molecules, despite
retaining the pyrazole, sulfonamide, and to some extent the
piperazine interactions (Figure 3F). The piperazine moiety of
63 forms two strong hydrogen bonds with excellent geometry
to the solvent network around the C-terminal carboxylate. In
the case of 59 two potential hydrogen bonds can be fulfilled,
first to the well conserved water molecule described for 42 and
to the side chain carbonyl of Asn167; however, the geometry of
these interactions is suboptimal with the stronger of the two
hydrogen bonds formed directly to the asparagine side chain.
The meta-substitution of 63 allows the molecule to access a
greater range of spatial orientations as opposed to the linear
para-substitution of 59 which results in a strained conformation
within the active site, suggesting that entropic constraints play a
significant role in binding. The reduced enzyme activity of the
para-substituted molecules may be attributed to a combination
of the steric constraint and the suboptimal hydrogen bonding
network around the C-terminal carboxylate.
■ CONCLUSION
Chemistry-driven optimization of a screening hit has resulted in
the discovery of pyrazolesulfonamide DDD85646 (63), a highly
potent, trypanocidal, orally active prototype inhibitor of
TbNMT, which cures rodents of systemic infection with T. b.
brucei and T. b. rhodesiense strains. As previously reported, a
number of biological studies have already established that 63
acts on target:17 (i) overexpression of TbNMT in T. brucei
(5-fold) led to a reduced sensitivity to 63 (8-fold); (ii) incubation
of the parasites with 63 prevented incorporation of radiolabeled
myristoyl-CoA into proteins; (iii) more generally over the
series, there was a good correlation between inhibition of the
enzyme and inhibition of parasite growth in culture. The
precise mechanism by which inhibition of NMT causes its
antiparasitic effects is not known. However, we suggest that a
pleiotropic effect, caused by the inhibition of myristoylation of
multiple important substrates, accounts for the effectiveness of
63 in cell culture and in vivo.
Although during this program we did not have structural
information to guide inhibitor design, we are presently able to
rationalize SAR using the structural information gained from
surrogate crystallography in LmNMT. The majority of residues
lining the active site are conserved between the T. brucei and
human NMT enzymes, which may explain why many of the
inhibitors including 63 show little selectivity. In the absence of
a structure of TbNMT, we are unable to delineate useful
differences between HsNMT and TbNMT that could inform
the design of selective inhibitors. However, compounds within
this series, such as 42, can possess a promising level of
selectivity.
We have discovered a useful prototype inhibitor of TbNMT
that is trypanocidal, has good oral pharmacokinetics, and is
effective in acute models of disease, thus allowing us to
successfully validate TbNMT as a target for drug discovery. The
limitations of 63, its inability to cross the blood−brain barrier
and lack of selectivity against HsNMT, are clearly factors that
need to be addressed. Work is currently ongoing to optimize
the selectivity and pharmacokinetic properties of compounds
within this series to identify potential clinical candidates that
can deliver an efficacious free concentration in the brain at a
well-tolerated dose.
■ EXPERIMENTAL SECTION
General Experimental Information. Chemicals and solvents
were purchased from Aldrich Chemical Co., Fluka, ABCR, VWR,
Acros, Fisher Chemicals, and Alfa Aesar and were used as received
unless otherwise stated. Air- and moisture-sensitive reactions were
carried out under an inert atmosphere of argon in oven-dried
glassware. Analytical thin-layer chromatography (TLC) was performed
on precoated TLC plates (layer 0.20 mm silica gel 60 with fluorescent
indicator UV254, from Merck). Developed plates were air-dried and
analyzed under a UV lamp (UV 254/365 nm). Flash column
chromatography was performed using prepacked silica gel cartridges
(230−400 mesh, 40−63 μm, from SiliCycle) using a Teledyne ISCO
Combiflash Companion or Combiflash Retrieve. 1H NMR and 13C
NMR spectra were recorded on a Bruker Avance II 500 spectrometer
(1H at 500.1 MHz, 13C at 125.8 MHz) or a Bruker DPX300 spectro-
meter (1H at 300.1 MHz). Chemical shifts (δ) are expressed in ppm
recorded using the residual solvent as the internal reference in all cases.
Signal splitting patterns are described as singlet (s), doublet (d), triplet
(t), quartet (q), pentet (p), multiplet (m), broad (br), or a combina-
tion thereof. Coupling constants (J) are quoted to the nearest 0.1 Hz.
LC−MS analyses were performed with either an Agilent HPLC 1100
series connected to a Bruker Daltonics MicrOTOF or an Agilent
Technologies 1200 series HPLC connected to an Agilent Tech-
nologies 6130 quadrupole spectrometer, where both instruments were
connected to an Agilent diode array detector. LC−MS chromatographic
separations were conducted with a Waters Xbridge C18 column,
50 mm × 2.1 mm, 3.5 μm particle size; mobile phase, water/acetonitrile +
0.1% HCOOH, or water/acetonitrile + 0.1% NH3; linear gradient
from 80:20 to 5:95 over 3.5 min and then held for 1.5 min; flow rate of
0.5 mL min−1. All assay compounds had a measured purity of ≥95%
(by TIC and UV) as determined using this analytical LC−MS system.
High resolution electrospray measurements were performed on a
Bruker Daltonics MicrOTOF mass spectrometer. Microwave-assisted
chemistry was performed using a Biotage initiator microwave
synthesizer. Compounds 25, 26, 33, and 34 were purchased from
Enamine as solids. Purity (>97%) and molecular mass were confirmed
by HPLC and high resolution mass spectrometry.
Prototypical Procedure for Preparation of a Sulfonamide
from an Amine and a Sulfonyl Chloride. 4-Methoxy-2,3,6-
trimethyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
(1). 4-Methoxy-2,3,6-trimethylbenzenesulfonyl chloride (500 mg, 2.0
mmol) was added portionwise to a stirred solution of 4-amino-1,3,5-
trimethyl-1H-pyrazole (250 mg, 2.0 mmol) in pyridine (10.0 mL) at
room temperature. The mixture was stirred for 24 h and then
concentrated to dryness in vacuo. The resulting residue was diluted
with DCM and washed with saturated aqueous NaHCO3. The organic
phase was separated, dried (MgSO4), filtered, and concentrated to
dryness in vacuo. Trituration from Et2O and collection by vacuum
filtration gave the title compound 1 as a fine off-white solid (380 mg,
1.13 mmol, 57%). 1H NMR (500 MHz, DMSO-d6): δ 8.87 (s, 1H),
6.67 (s, 1H), 3.48 (s, 3H), 3.28 (s, 3H), 2.33 (s, 3H), 2.21 (s, 3H),
2.01 (s, 3H), 1.77 (s, 3H), 1.54 (s, 3H). HRMS (m/z ): [MH+] calcd
for C16H24N3SO3, 338.1533; found 338.1533.
4-Bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-
benzenesulfonamide (29).17 Compound 29 was prepared from 4-
bromo-2,6-dichlorobenzenesulfonyl chloride (5.0 g, 15.4 mmol) and
4-amino-1,3,5-trimethyl-1H-pyrazole (1.93 g, 15.4 mmol) in pyridine
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(35.0 mL) according to the method of 1, to give the title compound 29
as an off-white solid (5.64 g, 13.7 mmol, 89%). 1H NMR (300 MHz,
DMSO-d6): δ 9.75 (s, 1H), 8.00 (s, 2H), 3.57 (s, 3H), 1.93 (s, 3H),
1.72 (s, 3H). HRMS (m/z): [MH+] calcd for C12H13N3SO2Cl2Br,
411.9283; found 411.9282.
6-Chloropyridine-3-sulfonic Acid (1,3,5-Trimethyl-1H-pyrazol-4-
yl)amide (37). 37 was prepared from 6-chloropyridine-3-sulfonyl
chloride (4.8 g, 22.7 mmol) and 4-amino-1,3,5-trimethyl-1H-pyrazole
(2.84 g, 22.7 mmol) in pyridine (35.0 mL) according to the method of
1, to give the title compound 37 as an off-white solid (5.13 g, 17.1
mmol, 75%). 1H NMR (500 MHz, DMSO-d6): δ 9.51 (s, 1H), 8.59 (d,
J = 2.3 Hz, 1H), 8.03 (dd, J = 7.6 Hz, 2.3 Hz, 1H), 7.77 (d, J = 7.6 Hz,
1H), 3.58 (s, 3H), 1.84 (s, 3H), 1.63 (s, 3H). HRMS (m/z ): [MH+]
calcd for C11H14N4SO2Cl, 301.0521; found 301.0523.
Prototypical Procedure for N-Alkylation of Compound
2. N-(1-Propyl-3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-tri-
methylbenzenesulfonamide (3). A solution of N-(3,5-dimethyl-1H-
pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide 2 (100 mg,
0.31 mmol), cesium carbonate (202 mg, 0.62 mmol), and 1-
bromopropane (76 mg, 0.62 mmol) in DMF (10.0 mL) was heated
to 80 °C for 1 h in a microwave. The mixture was partitioned between
ethyl acetate (25 mL) and brine (25 mL), dried (MgSO4), filtered, and
concentrated to dryness in vacuo. The resulting residue was purified by
column chromatography (SiO2, 1:1 ethyl acetate/hexane) to give the
title compound as an off-white solid (27 mg, 0.07 mmol, 24%). 1H
NMR (500 MHz, DMSO-d6): δ 8.67 (s, 1H), 6.45 (s, 1H), 4.46 (t, J =
6.9 Hz, 2H), 3.78 (s, 3H), 2.58 (s, 3H), 2.36 (s, 3H), 2.16 (s, 3H),
2.04 (s, 3H), 1.98 (m, 2H), 1.83 (s, 3H), 1.21 (t, J = 6.9 Hz, 3H).
HRMS (m/z): [MH+] calcd for C18H28N3SO3, 366.1846; found
366.1847.
Prototypical Procedure for Preparation of a 2-Aminopyridine
by SNAr Reaction of 2-Chloropyridine (37) with an Alkyl-
amine. 6-[2-(4-Methylpiperazin-1-yl)ethylamino]pyridine-3-sul-
fonic Acid (1,3,5-Trimethyl-1H-pyrazol-4-yl)amide (42). 6-Chloro-
N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide (37) (225 mg,
0.75 mmol) and 4-(2-aminoethyl)methylpiperazine (215 mg,
1.5 mmol) in ethanol (2.0 mL) were heated at 155 °C for 1 h by
microwave in a sealed vessel. Dilution with DCM (25 mL), washing
with saturated aqueous sodium hydrogen carbonate solution (2 ×
5 mL), drying (MgSO4), and concentration in vacuo gave a residual oil
which was subjected to chromatography (SiO2, 10:90 MeOH/EtOAc)
to give the title compound as an off-white powder (198 mg, 0.49
mmol, 65%). 1H NMR (300 MHz, DMSO-d6): δ 8.77 (s, 1H), 8.07
(d, J = 2.2 Hz, 1H), 7.45 (dd, J = 2.2 Hz, 8.9 Hz, 1H), 7.28 (s br, 1H),
6.54 (d, J = 8.9 Hz, 1H), 3.57 (s, 3H), 3.44−3.39 (m, 2H), 2.41 (t, J =
6.1 Hz, 2H), 2.41 (s br, 4H), 2.36−2.31 (s br, 4H and 3H), 2.16 (s,
3H), 1.89 (s, 3H), 1.67 (s, 3H). HRMS (m/z ): [MH+] calcd for
C18H30N7SO2, 408.2176; found 408.2185.
Prototypical Procedure for the Suzuki Reaction between an
Aryl Bromide and a Boronic Acid/Boronate Ester. 2,6-Dichloro-
4-(2-piperazin-1-ylpyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-
benzenesulfonamide (63).17 A deoxygenated solution of 4-bromo-
2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
(29) (13.84 g, 33.3 mmol), 2-(1-piperazinyl)pyridine-4-boronic acid
pinacol ester (11.57 g, 40.0 mmol), tribasic potassium phosphate (9.73 g,
44.0 mmol), and Pd(PPh3)4 (1.50 g, 0.96 mmol) in DMF (200 mL)
and water (40 mL) in a round-bottomed flask under argon was heated
at 120 °C for 1 h. The reaction mixture was then concentrated in
vacuo, diluted with DCM (400 mL), washed with saturated aqueous
ammonia solution (2 × 100 mL), dried (MgSO4), and concentrated in
vacuo. The residual solid was triturated from Et2O and collected by
filtration to give a solid which was recrystallized from EtOAc to give
the title compound 63 as an off-white powder (15.22 g, 30.7 mmol,
92%). 1H NMR (500 MHz, DMSO-d6): δ 9.79 (s, 1H), 8.25 (d, J =
5.9 Hz, 1H), 8.20 (s, 2H), 7.61 (s, 1H), 7.40 (d, J = 5.9 Hz, 1H),
4.08 (s br, 4H), 3.63 (s, 3H), 3.28 (s br, 4H), 2.00 (s, 3H), 1.77 (s,
3H). 13C NMR (125 MHz, DMSO-d6): 147.5, 147.3, 143.8, 137.4,
136.3, 135.2, 129.8, 111.8, 111.7, 109.1, 108.9, 42.7, 42.0, 36.2, 10.4.
HRMS (m/z): [MH+] calcd for C21H25N6SO2Cl2, 495.1131; found
495.1124.
Enzyme Inhibition Assay. N -Myristoyltransferase is an enzyme
that catalyzes the addition of myristic acid from myristoyl-CoA to the
N-terminal glycine residue of numerous substrate proteins and
peptides with the subsequent release of coenzyme A. 3H-labeled
myristoyl-CoA (GE Healthcare) can be used in the reaction to transfer
3H-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQ-
PPQAK(biotin)-amide, Pepceuticals Inc.). The reaction can be measured
by the subsequent binding of the labeled peptide to streptavidin-
coated scintillation proximity assay (SPA) beads (GE Healthcare) and
monitoring of β-particle excitation of the embedded scintillant (Figure 1).
Measurement of the ability of compounds to inhibit the N-
myristoyltransferase enzyme(s) of human (HsNMT-1 and HsNMT-2)
and kinetoplast (T. brucei, T. cruzi, and L. major) species was per-
formed using a modification of the scintillation proximity assay
platform described previously by Panethymitaki et al.20 as follows:
Compounds were solubilized in DMSO at a top concentration of
10 mM and serially diluted in half log steps to achieve a range of final
assay concentrations of 100 μM to 1.5 nM. Compound at each
concentration was added to white 384-well plates in a volume of
0.5 μL. N-Myristoyltransferase enzyme (HsNMT-1, HsNMT-2,
TcNMT, TbNMT, or LmNMT), dissolved to a working concentration
of 10 nM in assay buffer (30 mM Tris-HCl, pH 7.4, 0.5 mM EGTA,
0.5 mM EDTA, 1.25 mM DTT, 0.1% Triton X-100), was then added
to columns 1−11 and 13−23 of the plates in a volume of 20 μL. To
columns 12 and 24, 20 μL of assay buffer was added to provide a no
enzyme control. Following a 5 min incubation at room temperature
the substrates (GCGGSKVKPQPPQAK(biotin)-amide and myristoyl-
CoA), dissolved in assay buffer, were added to all wells in a volume of
20 μL to start the reaction. The final concentrations of peptide and
3H-myristoyl-CoA were 0.5 μM and 125 nM, respectively, and the
specific activity of the radiolabel was 8 Ci/mmol. Plates were then
incubated at room temperature for up to 50 min (dependent upon the
period of linearity for the different enzyme species) before SPA beads,
suspended to 1 mg/mL in a stop solution (200 mM phosphoric acid/
NaOH, pH 4, 750 mM MgCl2), were added in a volume of 40 μL.
Plates were then read on a TopCount microplate luminometer and
data analyzed by calculating the percentage inhibition compared to the
maximum and minimum assay controls. Concentration effect curves
were fitted using nonlinear regression using XLFit 4.2, and IC50 values
were determined.
Cell Viability Assay. Measurement of the ability of the com-
pounds to inhibit human (MRC5, human lung fibroblast cells) and
trypanosome (T. b. brucei, BSF427, VSG118) cell growth was performed
using a modification of the cell viability assay previously described by
Raz et al.29 Compounds were dissolved in DMSO at a top concentration
of 10 mM and serially diluted in half log steps to achieve a range of final
assay concentrations of 50 μM to 0.5 nM. Compound at each
concentration (200-fold final) was added to clear 96-well tissue culture
plates in a volume of 1 μL. Then 2000 cells per well in relevant growth
medium (HMI-9T for T. brucei, a modification of HMI-9 as described by
Hurumi et al.,30 where 0.2 mM 2-mercaptoethanol was replaced with
0.056 mM thiolglycerol, and MEM with 10% FBS for MRC5) were then
added to columns 1−11 of the plates in a volume of 199 μL. To column
12, 200 μL of medium was added to provide a no cells control. Plates
were then incubated at 37 °C in an atmosphere of 5% CO2 for 69 h,
before the addition of 20 μL of 500 μM rezasurin solution, and a further
incubation period of 4 h. Plates were then read on a BioTek flx800
fluorescent plate reader, and percentage inhibition was compared to the
maximum and minimum assay controls. Concentration effect curves were
fitted using nonlinear regression using XLFit 4.2 and EC50 values
determined.
Crystallography. The expression construct for 6xHis-TEV site,
LmNMT (5-421), was obtained from the Structural Genomics
Consortium (SGC), Toronto, Canada. The protein was expressed in
E. coli Rosetta (DE3) using autoinduction medium. Cells were
harvested by centrifugation and resuspended in 50 mM HEPES,
pH 7.5, 0.5 M NaCl, 5 mM imidazole, 5% glycerol (plus DNase,
lysozyme, and a protease inhibitor cocktail) and lysed by passage
through a constant cell disruptor (Constant Cell Systems).
Chromatography steps were carried out using an AKTA system
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(GE Healthcare). The lysate was cleared by centrifugation (50K rcf 30 min)
and loaded onto a 5 mL HisTRAP crude column (GE Healthcare),
and target protein was eluted by a 5−250 mM imidazole gradient.
Fractions containing LmNMT were pooled, desalted, and applied to a
6 mL Resource-Q column pre-equilibrated with 10 mM HEPES, pH
7.5. LmNMT was eluted by 0−500 mM NaCl gradient, and fractions
were analyzed by SDS−PAGE with fractions greater than 95% purity
concentrated to 9 mg/mL for crystallization.
Crystals of LmNMT with myristoyl-CoA were obtained by
incubating the protein with 1 mM myristoyl-CoA for 1 h at 4 °C
prior to crystallization. Protein crystals were obtained via the hanging
drop vapor diffusion method by mixing 2 μL of protein solution mixed
with 2 μL of reservoir solution that consisted of 24−30% PEG1500,
0.2 M NaCl, and 0.1 M Na cacodylate, pH 5.6. Rod shaped crystals
appeared after 2−4 days at 20 °C.
Protein−ligand complexes were obtained by soaking the crystals for
16 h in mother liquor derived cryoprotectant (25% PEG1500, 0.2 M
NaCl, 0.1 M Na cacodylate, pH 5.6, 20% glycerol) + 15 mM ligand,
prepared from a stock concentration of 0.2 M in DMSO. Crystals were
flash frozen in liquid nitrogen and stored before data measurement.
X-ray diffraction data were measured at the ESRF using beamlines
ID-29 and ID23-2 and the data reduced using the HKL suite.31 Molecular
replacement was carried out using MOLREP32 with the binary LmNMT +
myristoyl-CoA structure (PDB code 3H5Z) used as a search model.
The models were refined using REFMAC5,33 and manual alteration
was carried out using COOT34 with ligand coordinate and topology
files created with PRODRG.35 Coordinates and associated diffraction
data for complexes of LmNMT + 1, 29, 42, 62, and 59 have been
deposited in the Protein Data Bank (PDB) with accession codes 4A2Z,
4A30, 4A31, 4A32, and 4A33, respectively.
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